𝓤𝓷𝓲𝓽𝓮𝓭 𝓝𝓮𝔀𝓼

Drug maker AstraZeneca has announced plans to invest 50 billion dollars (£37 billion) in the US over the next five years amid the looming threat of President Donald Trump’s trade tariffs.

The Cambridge-headquartered firm said the investment will fund a new “state-of-the-art” manufacturing facility in Virginia – set to be its largest single manufacturing investment in the world.

It will also expand research and development (R&D) and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas.

The announcement marks the latest by a global pharmaceutical giant to expand its footprint in the US as Mr Trump has threatened to impose tariffs of up to 20% on drug imports in an effort to increase manufacturing in America and drive down costs for Americans.

AstraZeneca said the mammoth investment will create tens of thousands of jobs across the US, “powering growth and delivering next-generation medicines for patients in America and worldwide”.

The Anglo-Swedish group, which is listed on the FTSE 100, said the investment will also help it towards the group’s target of reaching 80 billion US dollars (£59.4 billion) in revenues by 2030.

Half of this is expected to come from the US, it added.

Pascal Soriot, chief executive of AstraZeneca, said: “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally.”

Despite being headquartered in the UK, America is AstraZeneca’s largest market, where it employs more than 18,000 staff and makes 42% of total group sales.

It already has 19 R&D, manufacturing and commercial sites across the country.

The new factory planned for Virginia will produce drug substances for the company’s weight management and metabolic portfolio, it said.

Howard Lutnick, US Secretary of Commerce, said: “For decades Americans have been reliant on foreign supply of key pharmaceutical products.

“President Trump and our nation’s new tariff policies are focused on ending this structural weakness.

“We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores.”